Mar 04, 2021 / 04:10PM GMT
Doug Schenkel - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
All right. Good morning, everybody. I'm Doug Schenkel from Cowen's life science and diagnostic tools team. It's my pleasure to welcome management from Agilent to the 41st Annual Cowen and Company Healthcare Conference. From the company, we have Mike McMullen, the company's Chief Executive Officer; Bob McMahon, Chief Financial Officer; Sam Raha, President of DGG; and Ankur Dhingra, the Head of Investor Relations. Gentlemen, thanks to all of you for joining us this morning and taking the time.
Mike, you've been doing a terrific job positioning the company for sustained above-peer-group growth through organic and strategic acquisitions. I know it's been great to see how the company has evolved under your leadership. I know you're not doing it alone. The other folks on the screen and all of your colleagues have been rowing hard moving along. We have a bunch of questions to ask you on the business, on the end markets and, of course, on the most recent announcement on your pending acquisition of Res Bio.
Agilent Technologies Inc at Cowen Healthcare Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers